Patents Assigned to Sinoclone Ltd.
  • Patent number: 10792275
    Abstract: The present invention is a method of inhibiting the replication of an influenza virus by using an antiviral compound to inhibit the binding of an influenza-virus PB2 subunit to an RNA cap. The antiviral compound may be 5-iodo-2-[(3-methyl-4-nitrobenzoyl)amino]benzoic acid; 3,3?-[(4-methylphenyl)methylene]bis(4-hydroxy-2H-chromen-2-one); or 7-(4-hydroxy-2-oxo-2H-chromen-3-yl)-6H,7H,8Hchromeno[3,4?:5,6]pyrano[3,2-c]chromene-6,8-dione. The aforementioned antiviral compounds have successfully inhibited the replication of influenza virus in vitro and in vivo in mouse models.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: October 6, 2020
    Assignee: Sinoclone Ltd
    Inventors: Bojian Zheng, Shuofeng Yuan, Yi Tsun Richard Kao, Jie Zhou
  • Publication number: 20190142785
    Abstract: The present invention provides a compound as shown in formula (I), formula (II), or formula (III), which can inhibit the binding of influenza virus PB2 protein to RNA cap and has an anti-influenza effect.
    Type: Application
    Filed: April 12, 2017
    Publication date: May 16, 2019
    Applicant: Sinoclone Ltd.
    Inventors: Bojian ZHENG, Shuofeng YUAN, Richard Yi Tsun KAO, Jie ZHOU